• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

September 12, 2014

Daily Low-Dose Aspirin Recommended to Prevent Preeclampsia, Preterm Birth

Author(s):

Michael R. Page, PharmD, RPh

Roughly 1 in every 3 obstetric complications are related to preeclampsia.

Roughly 1 in every 3 obstetric complications are related to preeclampsia.

Worldwide, 2% to 8% of all pregnant women develop preeclampsia, resulting in harm to both the mother and fetus.

Of the obstetric complications that occur in the United States each year, approximately 1 in 3 are related to preeclampsia. Additionally, preeclampsia and eclampsia cause approximately 12% of all maternal deaths in the country.1

To improve these statistics, new preventive recommendations from the United States Preventive Services Task Force (USPSTF) advise women at high risk for developing preeclampsia to take an 81-mg tablet of aspirin daily, starting at 12 to 28 weeks of gestation.1

Risk Factors and Signs

Factors that place women at high risk for preeclampsia include1:

  • Past cases of preeclampsia
  • Simultaneous fetal gestation
  • Chronic hypertension
  • Type 1 or type 2 diabetes mellitus
  • Having renal disease, and
  • Having any autoimmune disease

Each of these factors increases a pregnant woman’s risk of developing preeclampsia to approximately 8%.1

Laboratory abnormalities associated with preeclampsia include high blood pressure (140/90 mm Hg), and, in women who are beyond 20 weeks' gestation, high protein levels in urine (0.3 grams or more excreted in urine within 24 hours). Other abnormalities associated with preeclampsia include thrombocytopenia, impaired liver function, renal insufficiency, pulmonary edema, and cerebral or visual disturbances.1

Magnitude of Benefit and Evidence Base

Among women at high risk for developing preeclampsia, a daily dose of 60 to 150 mg of aspirin reduces the likelihood of developing preeclampsia by approximately 24%, preterm birth caused by preeclampsia by 14%, and intrauterine growth restriction by 20%.1,2

The change to recommendations occurred primarily as a result of a systematic evidence review and meta-analysis published in the May 2014 edition of the Annals of Internal Medicine. Of the qualifying studies obtained, the researchers included 2 large studies, 13 smaller studies, 6 randomized controlled trials, and 2 observational studies in their analysis.2-7

Based on an absolute risk reduction between 2% and 5%, the researchers estimated that, in order to prevent 1 additional case of preeclampsia, between 20 and 50 additional patients at high risk for the pregnancy complication would need to take a low-dose aspirin daily. Similarly, preventing 1 case of intrauterine growth restriction would require treating 20 to 100 additional patients with aspirin, while preventing 1 additional case of preterm birth would require treating 25 to 50 additional patients.2

Risks of Treatment

Use of aspirin in pregnant women was not associated with any adverse outcomes in those at high risk for preeclampsia. Importantly, however, the studies included in the metaanalysis did not evaluate long-term outcomes. Therefore, future studies may be required to fully elucidate the risks of aspirin use during pregnancy. As with any recommendation, it is important to take into account each patient’s clinical condition, risk factors, and medical history.2

References:

1. Lefevre M; for the US Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from Preeclampsia: US Preventive Services Task Force recommendation statement [published online September 9, 2014]. Ann Intern Med. 2014.

2. Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the US Preventive Services Task Force. Ann Intern Med. 2014;160(10):695-703.

3. Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1993;329(17):1213-1218.

4. Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998;338(11):701-705.

5. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007.

6. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369(9575):1791-1798.

7. CLASP collaborative group. Low dose aspirin in pregnancy and early childhood development: follow up of the collaborative low dose aspirin study in pregnancy. CLASP collaborative group. Br J Obstet Gynaecol. 1995;102(11):861-868.

Related Videos
Happy elderly patient with medical health checkup with cardiologist or geriatric doctor. Senior old aging woman with coronary artery heart disease or cardiac illness check-up in clinic - Image credit: Chinnapong | stock.adobe.com
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Related Content
Advertisement
Used empty packaging from pills close up. Many different pill blister silver pharmaceutical packaging foils. Drug shortage concept - Image credit: Sopear | stock.adobe.com
May 15th 2025

Medication Meltdown: Unpacking Drug Shortages

Kortney J. Knudsen, BS
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
X-ray image depicting a migraine -- Image credit: peterschreiber.media | stock.adobe.com
May 15th 2025

FDA Approves Brekiya, First and Only DHE Autoinjector, for Acute Treatment of Migraine, Cluster Headaches

Gillian McGovern, Associate Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Vitamin A supplements -- Image credit: 1989STUDIO | stock.adobe.com
May 15th 2025

Evidence Over Anecdotes: The Misuse of Vitamin A During Measles Outbreaks

Curtis E. Haas, PharmD, FCCP
Zepbound (tirzepatide) -- Image credit: Douglas | stock.adobe.com
May 14th 2025

CVS Health Announces It Will Drop Zepbound and Prioritize Coverage of Wegovy

Gillian McGovern, Associate Editor
Related Content
Advertisement
Used empty packaging from pills close up. Many different pill blister silver pharmaceutical packaging foils. Drug shortage concept - Image credit: Sopear | stock.adobe.com
May 15th 2025

Medication Meltdown: Unpacking Drug Shortages

Kortney J. Knudsen, BS
Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management
May 6th 2025

Pharmacists Can Be At the Forefront of Cardio-Kidney-Metabolic Management

Aislinn Antrim, Managing Editor Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP
X-ray image depicting a migraine -- Image credit: peterschreiber.media | stock.adobe.com
May 15th 2025

FDA Approves Brekiya, First and Only DHE Autoinjector, for Acute Treatment of Migraine, Cluster Headaches

Gillian McGovern, Associate Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
March 31st 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Vitamin A supplements -- Image credit: 1989STUDIO | stock.adobe.com
May 15th 2025

Evidence Over Anecdotes: The Misuse of Vitamin A During Measles Outbreaks

Curtis E. Haas, PharmD, FCCP
Zepbound (tirzepatide) -- Image credit: Douglas | stock.adobe.com
May 14th 2025

CVS Health Announces It Will Drop Zepbound and Prioritize Coverage of Wegovy

Gillian McGovern, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.